Welcome to ETERNAL's first newsletter. Amongst other things this edition features news on early progress made, perspectives on ETERNAL's theme's and ambitions, research into how biopharmaceutical processes can be made “greener by design” using genome engineering, and the opportunities presented by the new European Unitary Patent system.

Representatives of the ETERNAL project team are already mobilizing to reach out to the world beyond our consortium, getting out and about to introduce the project and to learn more from others. Find out more about some productive early cross-project discussions and plans to engage with our target stakeholders later in the year at the CPHI Europe show in Barcelona. We hope to see you there!

The European Unitary Patent (EUP) represents a new era for Intellectual Property (IP) protection for European small and medium enterprises (SMEs), industry and researchers, as well as a significant milestone in the evolution of IP protection across the EU member states. Find out more about the possibilities opened up by EUP and how they may affect how you protect your intellectual property in future.

Meet Prof. Andriy Luzhetskyy and Alina Zayachkivska from the the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) who are focused on metabolic engineering of actinobacteria

ETERNAL’s Technical Co-ordinator Raquel Llorens-Chiralt takes a few minutes to reflect upon the project’s overall themes and share her hopes and ambitions for how ETERNAL’s combination of collaborative research and co-created change activities can contribute to making pharmaceutical manufacture greener by design.

The ETERNAL consortium members enjoyed an energizing two days at the University of Aveiro when they gathered to mark the project’s six-month stage General Assembly meeting.

We are pleased to share this online version of a new brochure providing an overview of the essential features and key themes of the ETERNAL project.

A number of the ETERNAL project partners have been anticipating and outlining how they will be contributing to the project’s overall aim to establish safe and sustainable pharmaceutical lifecycles by design.

The recent launch of the ETERNAL project has generated some early press interest in our new four-year contribution to the sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, use, and disposal.

The ETERNAL project held a successful kick-off meeting in Valencia, Spain on 27th and 28th September. This new four-year EC Horizon Europe Research and Innovation Action will contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only active pharmaceutical ingredients and residues or metabolites, but other chemicals and by-products of the production process. In other words, safe and sustainable pharmaceutical lifecycles by design.